Pfizer second quarter revenue fell 1% in comparison to the corresponding quarter a year ago, down to $17bn despite a favourable foreign exchange.

Revenue was favourably effected by $740m due to foreign exchange, while the company also benefitted from the addition of legacy King products, which contributed $357m.

The decrease in revenues was largely attributed to the loss of exclusivity for several products, which resulted in a drop of $1.5bn, and US healthcare reforms, which were responsible for a revenue drop of $158m.

The company’s recorded a 9% decrease in US revenue to $6.7bn, while international revenues increased 5% to $10.3bn in comparison to the year-ago period.